Ask AI

Combating Myeloma: Improving Access and Outcomes With CAR T-Cell and Bispecific Antibody Therapies in Veterans With Relapsed/Refractory Multiple Myeloma

Learn more about patient and disease characteristics guiding the selection of CAR T-cell therapy and bispecific antibodies in the individualization of treatment of veterans with relapsed/refractory multiple myeloma and optimal strategies to integrate and sequence immunotherapies for these patients through an on-demand webcast, expert-authored commentary, and downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Clinical Care Options, LLC.

Supporters

Supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.

Bristol Myers Squibb

Johnson & Johnson